Study of Circulating Tumor DNA as a Blood Test to Detect, Characterize, and Monitor Colorectal Cancer in Patients Scheduled for Colonoscopy

What this Trial Is About

Researchers are evaluating the usefulness of circulating tumor DNA ctDNA markers found in blood as a liquid biopsy for diagnosing, predicting outcomes, and monitoring colorectal cancer. The study aims to determine if a panel of ctDNA markers can identify colorectal cancer patients among those scheduled for colonoscopy, and whether the type, number, and level of these markers vary with different colorectal cancer subtypes and their clinical progression. Participants will provide a blood sample and answer a questionnaire at the start of the study. Patients diagnosed with colorectal cancer will be asked to give an additional blood sample during their routine treatment and follow-up visits. This observational study does not involve any experimental treatments but focuses on collecting and analyzing blood samples to assess ctDNA markers. During the study, participants will undergo colonoscopy and be monitored for outcomes such as colorectal cancer, colorectal adenoma, and inflammatory bowel disease within three months after the procedure. Patients with colorectal cancer will be followed for up to five years to track recurrence, treatment response, and survival. The study includes questionnaires and blood tests to gather detailed information and monitor disease progression and response over time.

Circulating Tumor DNA in Patients Summoned for Colonoscopy; - a Liquid Biopsy for Detection, Characterization, Individualized Treatment and Follow-up of Colorectal Cancer